Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
ChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2379865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717201232199680 |
|---|---|
| author | Tiffany Dyu Char Leung Ana Cristina Simões-e-Silva |
| author_facet | Tiffany Dyu Char Leung Ana Cristina Simões-e-Silva |
| author_sort | Tiffany Dyu |
| collection | DOAJ |
| description | ChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database in Brazil. Individuals diagnosed with COVID-19 and schizophrenia were included in the study. The exposures were 0, 1, and 2 doses of ChAdOx1-S. The outcome of mortality was measured in hazard ratios (HR), calculated using multivariable Cox regression models. The study included 1,929 positive cases of COVID-19 in schizophrenia patients. After adjusting for age, socioeconomic factors, and comorbidities, we observed a significant 55% decrease in the hazard of mortality in the 2-dose vaccination group (HR 0.45, 95% CI: 0.310–0.652) compared to the unvaccinated. Surprisingly, our results did not show any significant reduction in the hazard of mortality in the 1 dose vaccination group (HR 1.278, 95% CI: 0.910–1.795). The effectiveness of two doses of ChAdOx1-S in individuals with schizophrenia aligns with findings from studies on the general population. That one dose was insignificant. Overall, these findings are important for informing public health decisions – prioritizing individuals with schizophrenia for vaccinations and managing acceptance of vaccines. |
| format | Article |
| id | doaj-art-386f26c461d94115b50abd6bd3f8fa00 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-386f26c461d94115b50abd6bd3f8fa002025-08-20T03:12:43ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2379865Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort studyTiffany Dyu0Char Leung1Ana Cristina Simões-e-Silva2School of Biological Sciences, University of Leicester, Leicester, UKDepartment of Population Health Sciences, University of Leicester, Leicester, UKFaculty of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilChAdOx1-S is a viral vector vaccine developed by AstraZeneca. We aimed to assess the effectiveness of 1 and 2 doses of the ChAdOx1-S vaccine in reducing COVID-19-related in-hospital mortality in individuals with schizophrenia. This is a retrospective cohort study using a nationwide hospital database in Brazil. Individuals diagnosed with COVID-19 and schizophrenia were included in the study. The exposures were 0, 1, and 2 doses of ChAdOx1-S. The outcome of mortality was measured in hazard ratios (HR), calculated using multivariable Cox regression models. The study included 1,929 positive cases of COVID-19 in schizophrenia patients. After adjusting for age, socioeconomic factors, and comorbidities, we observed a significant 55% decrease in the hazard of mortality in the 2-dose vaccination group (HR 0.45, 95% CI: 0.310–0.652) compared to the unvaccinated. Surprisingly, our results did not show any significant reduction in the hazard of mortality in the 1 dose vaccination group (HR 1.278, 95% CI: 0.910–1.795). The effectiveness of two doses of ChAdOx1-S in individuals with schizophrenia aligns with findings from studies on the general population. That one dose was insignificant. Overall, these findings are important for informing public health decisions – prioritizing individuals with schizophrenia for vaccinations and managing acceptance of vaccines.https://www.tandfonline.com/doi/10.1080/21645515.2024.2379865COVID-19SARS-CoV-2schizophreniamortalityvaccineChAdOx1-S |
| spellingShingle | Tiffany Dyu Char Leung Ana Cristina Simões-e-Silva Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study Human Vaccines & Immunotherapeutics COVID-19 SARS-CoV-2 schizophrenia mortality vaccine ChAdOx1-S |
| title | Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study |
| title_full | Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study |
| title_fullStr | Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study |
| title_full_unstemmed | Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study |
| title_short | Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study |
| title_sort | effectiveness of astrazeneca vaccine against sars cov 2 chadox1 s in reducing in hospital mortality in individuals with covid 19 and schizophrenia a retrospective cohort study |
| topic | COVID-19 SARS-CoV-2 schizophrenia mortality vaccine ChAdOx1-S |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2379865 |
| work_keys_str_mv | AT tiffanydyu effectivenessofastrazenecavaccineagainstsarscov2chadox1sinreducinginhospitalmortalityinindividualswithcovid19andschizophreniaaretrospectivecohortstudy AT charleung effectivenessofastrazenecavaccineagainstsarscov2chadox1sinreducinginhospitalmortalityinindividualswithcovid19andschizophreniaaretrospectivecohortstudy AT anacristinasimoesesilva effectivenessofastrazenecavaccineagainstsarscov2chadox1sinreducinginhospitalmortalityinindividualswithcovid19andschizophreniaaretrospectivecohortstudy |